Search Case Studies

Refine your results
1 - 10 results of 10 found.
  • Hereditary autoinflammatory disease programme: the NHS CAPS Treatment Service

    The UCL Centre for Amyloidosis & Acute Phase Proteins has identified the cause and treatment for the prototypical cryopryin associated periodic syndrome (CAPS), and subsequently for a range of other hereditary and acquired autoinflammatory disorders.

  • B cell depletion: an effective therapy in rheumatoid arthritis

    Pioneering UCL research in the 1990s into the mechanisms that cause rheumatoid arthritis established a new understanding of the disease. As a result, a new treatment – B cell depletion – has been introduced worldwide.

  • Introduction of aromatase inhibitors for the treatment of breast cancer

    The ATAC trial of a novel breast cancer treatment has resulted in a dramatic, global change in the management of the disease.

  • Advances in diagnosis and treatment of the haemolytic anaemias

    Research at UCL on human haemolytic anaemias, known as the ‘hereditary stomatocytoses’, has improved diagnosis of these conditions, and has raised awareness of the potential impact on donated blood.

  • CT colonography for diagnosis of colorectal cancer

    Investigation of the role of CT colonography led to this examination replacing the standard radiological alternative of barium enema in the UK National Bowel Cancer Screening Programme and for symptomatic patients in the NHS.

  • CardioQ: Improved surgical outcomes achieved through perioperative circulatory optimisation guided by oesophageal Doppler

    A new device – the CardioQ Oesophageal Doppler Monitor – used to monitor critically ill patients and those undergoing high-risk surgery has been used for over half a million patients and is recommended in NICE guidance.

  • Improving the management of systemic sclerosis

    Researchers at the UCL Centre for Rheumatology & Connective Tissue Disease have pioneered translational research in systemic sclerosis, resulting in better stratification, management and treatments for the condition.

  • Amyloidosis and acute phase proteins: world-leading clinical service

    Research has led to advances in the diagnosis of amyloidosis and clinical characterisation of many new subtypes that has led to new standards of clinical care, improved diagnosis, improved outcomes, and major investment by the NHS.

  • Drug development in an innovative model of collaboration between academia and industry

    Professor Sir Mark Pepys and his team in the UCL Wolfson Drug Discovery Unit have invented new chemical entities for treatment of amyloidosis, Alzheimer’s disease, and other conditions.

  • Acid-sensing ion channels: identifying pain mechanisms leads to development of potential treatments

    As a result of research on acid-sensing ion channels (ASICs) in pain regulation, ASIC-related therapies for a wide variety of conditions are now in clinical trials.

    1. 1